By Adam Bonislawski

Cambridge, Mass.-based BioScale announced this week that it has secured $25 million in a recent funding round led by new investor Morningside Venture.

The company will use the proceeds to fund commercialization of its recently launched ViBE protein analytics system, a label-free, non-optical protein detection and quantitation platform based on BioScale's proprietary Acoustic Membrane MicroParticle, or AMMP, technology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.